Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma
HAIC treatment provided superior survival benefits and a favorable safety profile compared to atezolizumab-bevacizumab in high-risk HCC patients.
Authors
- Yu-Nan Zhang
- Jie Xu (ORCID: https://orcid.org/0000-0003-1863-408X)
- Xintong Wu (ORCID: https://orcid.org/0000-0002-7676-3288)
- Yimin Zhang (ORCID: https://orcid.org/0000-0002-9962-3608)
- Ming Zhao (ORCID: https://orcid.org/0000-0002-1025-8895)
- Jun‐Zhe Yi (ORCID: https://orcid.org/0000-0002-0588-2060)
- Ning Lyu (ORCID: https://orcid.org/0000-0002-8254-1040)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- State Key Laboratory of Oncology in South China
Publication Details
- Journal
- Liver Cancer
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1159/000545891
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32